Breaking News

RedHill Biopharma Secures BARDA Funding to Advance Ebola Treatment

Opaganib has shown a statistically significant increase in survival time in an in vivo EBOV study.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, was selected by the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), a center of the Department of Health and Human Services (HHS)’ Administration for Strategic Preparedness and Response (ASPR), to advance opaganib2 to treat exposure to Ebola virus disease (EBOV).   Under this cost-sharing contract, BARDA will provide partial funding for the company to further advance opaganib to help mi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters